Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | CA12 | O43570 | 1/20 | 0.35 |
| ▸ | PARP1 | P09874 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6265298 | 0.98 | GPR3 (0.46) | GPR3ALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL7446614 | 0.74 | GPR3 (0.48) | GPR3ALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| Benzonaphthyridine SCHEMBL11311822 | 0.72 | GPR3 (0.58) | GPR3ALDH1A1SMN1; SMN2CYP1A2MAOA | |
| SCHEMBL1248587 | 0.71 | MAPT (0.58) | ALDH1A1SMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL25095968 | 0.70 | CYP1A2 (0.44) | GPR3ALDH1A1CYP1A2CYP2C19MAOA | |
| SCHEMBL22045624 | 0.70 | GPR3 (0.54) | GPR3ALDH1A1SMN1; SMN2CYP1A2CYP2C19 | |
| SCHEMBL276368 | 0.70 | GPR3 (0.37) | GPR3 | |
| SCHEMBL11270034 | 0.69 | MAPT (0.48) | ALDH1A1SMN1; SMN2CYP1A2MEN1KMT2A | |
| SCHEMBL13859950 | 0.68 | MAPT (0.54) | ALDH1A1CYP1A2MEN1KMT2AHTT | |
| SCHEMBL7904537 | 0.68 | PARP1 (0.42) | ALDH1A1CYP1A2CYP2C19MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112979658-B | Preparation method of flumazenil | 南湖实验室 | 2022-05-31 | — | — | CN | claimed |
| US-8063204-B2 | Benzothiazole and benzoxazole linked pyrrolo[2,1-c] [1, 4] benzodiazepine hybrids as novel antitumour agents and process for the preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2011-11-22 | — | — | US | claimed |
| EP-2350085-A1 | QUINAZOLINONE LINKED PYRROLOÝ2,1 -C¨Ý1.4¨BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF | Council Of Scientific & Industrial Research (IN) | 2011-08-03 | — | — | EP | claimed |
| WO-2010058416-A1 | QUINAZOLINONE LINKED PYRROLO[2,1 -C][1.4]BENZODIAZEPINE HYBRIDS AS POTENTIAL ANTICANCER AGENTS AND PROCESS FORTHE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2010-05-27 | — | — | WO | claimed |
| EP-2061795-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | Council Of Scientific&industrial Research (IN) | 2009-05-27 | — | — | EP | claimed |
| WO-2008020455-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-21 | — | — | WO | claimed |
| WO-2008020456-A2 | PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRIDS AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2008-02-21 | — | — | WO | claimed |
| WO-2007054954-A1 | A NOVEL PYRROLO[2,1-C][1,4]BENZODIAZEPINE HYBRID AND A PROCESS FOR THE PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2007-05-18 | — | — | WO | claimed |
| WO-2005089515-A9 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | BRIGHAM & WOMENS HOSPITAL (US) | 2006-01-26 | — | — | WO | claimed |
| WO-2005089515-A2 | METHODS FOR THE TREATMENT OF SYNUCLEINOPATHIES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2005-09-29 | — | — | WO | claimed |
| EP-1196412-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR XA INHIBITORS | Bristol-Myers Squibb Pharma Company (US) | 2002-04-17 | — | — | EP | claimed |
| WO-2001005784-A1 | NITROGEN CONTAINING HETEROBICYCLES AS FACTOR Xa INHIBITORS | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2001-01-25 | — | — | WO | claimed |
| EP-0987266-A1 | BIPHENYL DERIVATIVES AND MEDICINAL COMPOSITIONS | Wakamoto Pharmaceutical Co., Ltd. (JP) | 2000-03-22 | — | — | EP | claimed |
| EP-0393604-A2 | 6,11-Dihydro-5H-pyrido(2,3-b)(1,5,)benzodiazepin-5-ones and thiones and their use in the prevention or treatment of AIDS | BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) | 1990-10-24 | — | — | EP | claimed |
| JP-54090195-A | — | — | None | — | — | JP | disclosed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | disclosed |
| US-20250216392-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | SANOFI-AVENTIS (FR) | 2025-07-03 | — | — | US | disclosed |
| JP-S5490195-A | NOVEL BENZODIAZEPINE COMPOUND | GREEN CROSS CORP:THE | 1979-07-17 | — | — | JP | disclosed |
| US-4133809-A | DEPRESSANTS, TRANQUILIZERS, SEDATIVES, GROWTH PROMOTERS, ANTICONVULSANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1979-01-09 | — | — | US | disclosed |
| US-4111934-A | MUSCLE RELAXANT, ANTICONVULSANT, SEDATIVE | HOFFMANN-LA ROCHE INC. (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250216392-A1 | NOVEL ANTI-CD38 ANTIBODIES FOR THE TREATMENT OF CANCER | CD38, MCL1, CD2 | GPR3 1472/4885ALDH1A1 2209/4885SMN1; SMN2 1968/4885 |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | PRMT5, PRMT1, PRMT6 | GPR3 2326/4885ALDH1A1 3485/4885SMN1; SMN2 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.